Major histocompatibility complex class II expression on CD14 pos cells in canine peripheral blood across various hematologic disorders—a preliminary study

Read full text
Authors: Javier Martínez‐Caro, Beatriz Agulla, Marta Lemos, Josep Pastor
Cited by: 0
References: 24

Abstract

Monocytes are key cells of the immune system; various cell subsets have distinct phenotypic characteristics and functions. We characterized canine monocyte subsets in different hematologic disorders by analyzing peripheral blood cells for their expression of CD14 and major histocompatibility complex class II (MHCII). Flow cytometry data of canine blood samples were evaluated retrospectively. We assigned 132 total cases to one of the following categories: healthy, inflammatory, T-zone lymphoma/leukemia (TZL), T-cell chronic lymphocytic leukemia (CLL), B-cell CLL, T-cell stage V lymphoma (SVL), B-cell SVL, acute lymphoblastic or undifferentiated leukemia (ALL/AUL), or acute myeloid leukemia (AML). We analyzed age, sex, breed, light scatter properties, WBC count, CD14 pos cells, CD14 pos MHCII pos cells, CD14 pos MHCII neg cells, and the CD14 pos MHCII pos /CD14 pos MHCII neg ratio. All groups were compared with the healthy group. In healthy dogs, CD14 pos MHCII pos cells were larger and had a more complex internal structure than CD14 pos MHCII neg cells. Absolute numbers of CD14 pos MHCII neg cells were significantly increased in all groups except the TZL and B-cell SVL groups. Absolute numbers of CD14 pos MHCII pos cells were significantly increased in the T-cell CLL, B-cell CLL, and T-cell SVL groups, mildly increased in the inflammatory and TZL groups, and decreased in the ALL/AUL group. The CD14 pos MHCII pos /CD14 pos MHCII neg ratio was markedly decreased in both acute leukemia groups, being

Fields of Study & Subjects

Veterinary Oncology Research Animal health and immunology Veterinary Medicine and Surgery

Publication details

Journal / source
Journal of Veterinary Diagnostic Investigation
Volume
38
Issue
3
Pages
391–398
Publication date
26 January 2026
Language
EN